
CervoMed, Agape ATP, and CDT Equity are the three Penny stocks to watch today, according to MarketBeat’s stock screener tool. Penny stocks are shares of very small companies that trade at low prices, often under $5 per share, and usually on over-the-counter markets or smaller exchanges. They tend to be highly speculative and volatile, with lower liquidity and higher risk than more established stocks, which can make them attractive to some investors but dangerous for others. These companies had the highest dollar trading volume of any Penny stocks within the last several days.
CervoMed (CRVO)
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.
Agape ATP (ATPC)
Agape ATP Corporation, an investment holding company, supplies health and wellness products and health solution advisory services in Malaysia. It offers four series of programs that consist of various services and products under the ATP Zeta Health Program, ÉNERGÉTIQUE, BEAUNIQUE, and E.A.T.S. names.
Read Our Latest Research Report on ATPC
CDT Equity (CDT)
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Read Our Latest Research Report on CDT
Recommended Stories
- MarketBeat’s Top Five Stocks to Own in June 2026
- 3 Retail Winners Using Cash Flow to Stay Ahead
- 3 Tech ETFs That Could Bounce Back After the AI Selloff
- 3 Penny Stocks Under $5 Backed by Real Revenue Growth
- 3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend
- Beyond the AI Trade: 3 Defensive Stocks Built for Stability
